Drug Trial Radar · NCT07019779
Study of CM518D1 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
434
Planned (sponsor's estimate)
Start
Jun 27, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
CM518D1Biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
CM518D1Biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
CM518D1Biological
CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)-Phase I dose escalationTime frame: First cycle (21 days)
- Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose escalationTime frame: Through study completion, an average of 2 years.
- Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose expansionTime frame: Through study completion, an average of 2 years.]
- Preliminary efficacy-Phase I dose expansionTime frame: Through study completion, an average of 2 years.]
- Objective response rate (ORR)-Phase IITime frame: Through study completion, an average of 2 years.]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.